- Open Access
Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider
Critical Care volume 24, Article number: 603 (2020)
- The original article was published in Critical Care 2020 24:444
We read with great interest the recent article by Stallmach et al. who reported data from a small retrospective case series of patients with COVID-19 that received infliximab compared to a contemporaneous cohort that received supportive care alone . Infliximab (anti-TNF) was used to target proinflammatory cytokines that are associated with deterioration of organ function and poor outcomes in patients with COVID-19 [1, 2]. The authors reported that mortality was reduced from 35% in the control group to 14% in the infliximab group . We would like to make some comments. Looking at the baseline characteristics of the patients, we can see that ferritin levels in the infliximab group were almost double those in the control group (2777.4 vs 1453 μg/L) . It is possible that the patients in the treated group may have had secondary hemophagocytic lymphohistiocytosis (sHLH) syndrome induced by SARS-CoV-2 . The HScore, one of the tools to diagnose HLH, assigns no points to a ferritin below 2000 μg/L, while a ferritin between 2000 and 6000 μg/L adds 35 points, showing that the limit of 2000 μg/L is really crucial . Due to the massive cytokine release seen in patients with the condition, HLH is considered to be a cytokine storm syndrome . In potential sHLH, early use of high-dose steroids alone can be successful, consistent with the recent findings regarding the efficacy of dexamethasone in patients with severe COVID-19 receiving any form of respiratory support . Other drugs such as infliximab may be life-saving in this group of patients. In conclusion, on the basis of the difference in ferritin levels between the two groups and the potential diagnosis of sHLH, the two groups in this study are not well matched . A diagnosis of sHLH could explain the enormous cytokine storm responding so well to infliximab  and may also explain why dexamethasone is so effective in patients with severe COVID-19 . The sHLH-cytokine storm may be the main reason for the rapid deterioration seen in patients with COVID-19 . It is advisable to measure baseline ferritin before starting any immunological treatment in order to improve the efficacy .
To the editor:
We thank Dr. Honore and colleagues for their thoughtful comments pointing towards a potential secondary hemophagocytic lymphohistocytosis (sHLH) characterized by pancytopenia, hyper-coagulation, acute kidney injury, and hepatobiliary dysfunction associated with COVID-19. Based on their suggestion, we applied the hemophagocytosis score (HScore) and obtained a median Hscore of 171 (136;186) for IFX-treated patients and 136 (77; 182) for controls (p = 0.393) reflecting that some but not all of the patients fulfilled the HScore criterium of sHLH, i.e., a score above 169. Nevertheless, all of the patients displayed a profound inflammatory state in particular in the IFX-treated patients, reflecting the experimental therapeutic approach. A recent proposal by a panel of experts suggested to screen all patients with severe COVID-19 both for a hyperinflammatory state using laboratory tests (e.g., ferritin, decreased platelet count or erythrocyte sedimentation rate) and for the HScore to identify the subgroup of patients for whom immunosuppressive therapies (e.g., infliximab or anakinra ) could improve outcome . Whether severe COVID-19 indeed reflects a form of sHLH is still a matter of controversy; however, the evidence to support antiinflammatory interventions in the most severe cases is meanwhile supported by prospective randomized evidence for dexamethasone . Though, research addressing the optimum immune modulating drug, e.g., depending on the severity of the cytokine response, is warranted .
Availability of data and materials
Tumor necrosis factor
Secondary hemophagocytic lymphohistiocytosis
Hematophagocytic syndrome score
Stallmach A, Kortgen A, Gonnert F, Coldewey SM, Reuken P, Bauer M. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series. Crit Care. 2020;24(1):444. https://doi.org/10.1186/s13054-020-03158-0.
Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. https://doi.org/10.1016/j.ebiom.2020.102763.
Soy M, Atagündüz P, Atagündüz I, Sucak GT. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. Rheumatol Int. 2020:1–12. https://doi.org/10.1007/s00296-020-04636-y.
The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2021436.
Grangé S, Buchonnet G, Besnier E, Artaud-Macari E, Beduneau G, Carpentier D, et al. The use of ferritin to identify critically ill patients with secondary hemophagocytic lymphohistiocytosis. Crit Care Med. 2016;44(11):e1045–53. https://doi.org/10.1097/CCM.0000000000001878.
George Dimopoulos et al. Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe 2020;28(1):117–123.e1. doi: https://doi.org/10.1016/j.chom.2020.05.007. Epub 2020 May 14.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4 https://doi.org/10.1016/S0140-6736(20)30628-0.
Shrestha GS, Paneru HR, Vincent J. Precision medicine for COVID-19: a call for better clinical trials. Crit Care. 2020;24:282 https://doi.org/10.1186/s13054-020-03002-5.
Ethics approval and consent to participate
Consent for publication
The authors declare to have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Honore, P.M., Barreto Gutierrez, L., Kugener, L. et al. Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider. Crit Care 24, 603 (2020). https://doi.org/10.1186/s13054-020-03294-7